Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis & Investment Frameworks
Recursion Pharmaceuticals, Inc. (RXRX) stock analysis on Invetso. Review Recursion Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Recursion Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Recursion Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $1.92B
- Revenue: $74.68M
- ROE: -50.41%
- ROIC: -48.34%
- Dividend Yield: N/A
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Recursion Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes Recursion Pharmaceuticals, Inc. (RXRX) across the following frameworks:
- Recursion Pharmaceuticals, Inc. 10Y Growth Potential
- Recursion Pharmaceuticals, Inc. Scenario Analysis
- Recursion Pharmaceuticals, Inc. Risks & Opportunities
- Recursion Pharmaceuticals, Inc. Economic Moat
- Recursion Pharmaceuticals, Inc. Business Model
- Recursion Pharmaceuticals, Inc. Management
- Recursion Pharmaceuticals, Inc. SWOT Analysis
- Recursion Pharmaceuticals, Inc. Porter's 5 Forces
- Recursion Pharmaceuticals, Inc. PESTLE Analysis
- Recursion Pharmaceuticals, Inc. ESG Analysis